Merck KGaA announced plans today to beef up its R&D operations in Massachusetts.
Regeneron says that its anti-NGF pain drug fasinumab came through in a Phase II/III study for osteoarthritis patients.
Immunotherapy is revolutionizing how we perceive and treat cancer. Combination approaches are now at the forefront to combat the many ways cancers can adapt…
Two biotech companies, Bind Therapeutics and NephroGenex, are seeking the temporary protection of a Chapter 11 bankruptcy order as both look to a potential…
5AM Ventures has pieced together a syndicate to back a new biotech which they believe can forge a new way forward in gene editing.
Berg is taking its tech-enabled approach to drug development into the clinic by incorporating its machine-learning tool into a Phase II pancreatic cancer trial.
The Stanford Center for Genomics and Personalized Medicine has begun using DNAnexus’ platform for the analysis and sharing of sequencing data.
Acadia Pharmaceuticals has won its lengthy quest to gain an approval for Nuplazid (pimavanserin), a breakthrough antipsychotic.
In Q1 AstraZeneca discontinued 8 different programs--including a late-stage effort involving its closely watched checkpoint drug.
Nine months removed from Allergan’s rich $2.1 billion all-cash buyout, some of the top execs at Kythera have moved on to launch Sienna.
AbbVie and partner Biogen are on the cusp of being granted EU approval for their new MS drug.